EcoDrugPlus

A Disintegrin And Metallopeptidase Domain 17

Ensembl ID : ENSMSIG00000022289
Gene Symbol: ADAM17
1 Cross references
297 Possible Orthologues:

A Disintegrin-Like And Metallopeptidase (Reprolysin Type) With Thrombospondin Type 1 Motif, 5 (Aggrecanase-2)

Ensembl ID : ENSMSIG00000026620
Gene Symbol: ADAMTS5
1 Cross references
215 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSMSIG00000010105
Gene Symbol: ACHE
1 Cross references
248 Possible Orthologues:

Activin A Receptor, Type Ii-Like 1

Ensembl ID : ENSMSIG00000017719
Gene Symbol: ACVRL1
1 Cross references
368 Possible Orthologues:

Activin Receptor Iib

Ensembl ID : ENSMSIG00000003871
Gene Symbol: ACVR2B
1 Cross references
272 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSMSIG00000018036
Gene Symbol: ADORA1
1 Cross references
284 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSMSIG00000006083
Gene Symbol: ADORA2A
1 Cross references
275 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSMSIG00000018628
Gene Symbol: ADORA2B
1 Cross references
215 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSMSIG00000005809
Gene Symbol: ADORA3
1 Cross references
104 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSMSIG00000028618
Gene Symbol: ADA
1 Cross references
231 Possible Orthologues:

Adrenergic Receptor, Alpha 1a

Ensembl ID : ENSMSIG00000018756
Gene Symbol: ADRA1A
1 Cross references
216 Possible Orthologues:

Adrenergic Receptor, Alpha 1b

Ensembl ID : ENSMSIG00000023363
Gene Symbol: ADRA1B
1 Cross references
278 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).